The buyer across the table is no longer just pricing your earnings. They are pricing whether your patients will still show up after you cash the check.
A founder we worked with built a thriving multi-site specialty practice over fifteen years. Strong margins, loyal patients, a waitlist. When a private equity buyer came to the table, the founder assumed the conversation would be about EBITDA and a multiple. It was, but not the way he expected.
The buyer's team spent less time on the income statement and more time on a question the founder had never been asked: where do your patients actually come from, and what happens to that flow the day you stop showing up? They had pulled the practice's search visibility, mapped its review profile, modeled how much new-patient volume traced to the founder's personal reputation versus the brand, and stress-tested how dependent the whole engine was on a single referral relationship.
They were not pricing the practice. They were pricing its brand capital, the durable, transferable demand the business had built, and whether that demand would survive the transition. The number on the term sheet moved because of what they found.
Why Buyers Started Scoring the Brand
Healthcare has become one of the most active arenas for private equity roll-ups, dermatology, dental, behavioral health, ophthalmology, fertility, veterinary, and more. When a sector gets crowded with buyers, diligence gets sharper, because the easy value has already been bid away.
Sophisticated acquirers learned an expensive lesson from the first wave of roll-ups: a practice can have beautiful trailing financials and still crater after close. The usual culprits are not financial. They are demand-side:
The rainmaker problem. Half the new patients came because of one charismatic founding physician whose name was the brand. The doctor takes the earn-out, semi-retires, and the pipeline quietly collapses.
The paid-traffic treadmill. Growth looked great, but it was entirely rented, bought click by click. The moment the ad budget normalized, so did the volume.
The fragile referral. A huge share of cases flowed from one hospital relationship or one referring group that has no contractual reason to stay loyal to new ownership.
Each of these is a brand-capital deficiency, and each one is a reason for a buyer to either walk or pay less. So buyers built the muscle to detect them. Demand durability is now a diligence workstream, not an afterthought.
How Brand Capital Shows Up in the Multiple
The valuation logic is not mysterious. A multiple is the market's judgment about the quality and durability of future earnings. Two practices with identical EBITDA are not worth the same if one's earnings are durable and the other's are fragile.
Picture two behavioral health groups, each doing the same profit. The first gets most of its new patients from one founder's reputation and a paid-search account nobody fully understands. The second has diversified acquisition across organic search, a strong and growing review base, an owned email and content engine, and clean measurement showing a stable cost per patient across channels.
The second business is worth materially more, and a disciplined buyer will pay for it, because the risk of a post-close demand cliff is lower. The brand is doing work that does not walk out the door with any one person. Brand capital is the difference between selling a job and selling an asset.
The Four Things Diligence Now Tests
When marketing-aware capital evaluates a healthcare target, the brand examination tends to probe four areas:
Concentration. How diversified is patient acquisition? Is demand spread across channels and clinicians, or dangerously concentrated in one person, one platform, or one referrer?
Ownership. Is the demand owned or rented? Organic visibility, a real review moat, an engaged patient list, and branded search all read as owned. Pure paid dependency reads as rented and discounts accordingly.
Measurement. Can the business prove its numbers? A clean, compliant, first-party view of cost per patient and lifetime value signals a professional operation. Murky attribution signals risk and invites a lower offer.
Defensibility. Is the marketing compliant and durable? Aggressive tactics that could trigger a regulatory action, or tracking practices that create liability, are not just compliance problems; they are valuation problems, because the buyer inherits the exposure.
A target that scores well on these four does more than avoid markdowns. It gives the buyer a credible thesis for growing the asset, which is what justifies a premium in the first place.
A Tale of Two Exits
Consider two specialty groups that went to market the same year with nearly identical earnings. The first had grown fast on the strength of its founder, a regionally famous physician, and a paid-search account that one outside agency controlled and would not fully hand over. Diligence flagged both immediately. The founder's planned step-back read as a demand cliff; the rented, opaque paid channel read as a number nobody could trust. The buyer still wanted the asset, but they re-cut the offer, loaded it with earn-out tied to retention, and effectively transferred the demand risk back onto the seller.
The second group looked less glamorous on paper, no celebrity physician, a steadier growth curve, but its demand was diversified across several clinicians and channels, its review base was deep and current, and it owned a clean first-party view of how much a new patient cost and what they were worth over time. Diligence confirmed the story instead of puncturing it. That group closed at a higher multiple, with more cash up front and less contingent on the founder's continued presence.
Same earnings, different outcomes, and the gap was almost entirely brand capital. The first founder sold a business that needed him. The second sold one that did not. Buyers pay, in cash and in certainty, for the second kind.
The Founder's Mistake: Treating Marketing as an Expense
Most founders preparing to sell pour their energy into cleaning up the financials, the quality-of-earnings review, the add-backs, the working-capital normalization. That work matters. But they treat marketing as a line of cost to minimize before a sale, when the buyer is treating it as a source of value to underwrite.
That mismatch leaves money on the table. A founder who cuts marketing to juice short-term EBITDA can actually lower the sale price, because they have weakened the very demand engine the buyer is trying to value, and a sharp buyer sees the starved pipeline immediately.
The founders who maximize their outcome do the opposite. They build brand capital deliberately in the years before a process, so that when diligence comes, the answer to "where do your patients come from?" is a strong, diversified, well-documented story instead of a nervous one.
Building Brand Capital Before You Need It
This is not work you can fake at the term-sheet stage. Buyers can tell the difference between demand that was built and demand that was staged for a sale. The preparation has to start twelve to twenty-four months ahead and look organic, because it is. The priorities:
Diversify acquisition. Reduce dependence on any single channel, clinician, or referrer. Build owned channels, organic visibility, content, a patient list, that keep producing without a credit card attached.
Reduce key-person risk. Shift reputation from the founder's name to the brand. Develop other clinicians as credible faces. Make the institution, not the individual, the thing patients trust.
Get your measurement clean and compliant. A first-party, defensible view of cost per patient and lifetime value is both a growth tool and a diligence asset. Murky numbers cost you twice.
Make the marketing defensible. Eliminate tactics and tracking that create regulatory exposure. The buyer inherits your risk, and they price it.
The Asset You Are Actually Selling
When a healthcare business changes hands, the financials get the attention, but the brand increasingly sets the ceiling. A buyer is paying for future patients, and brand capital is their best evidence that those patients will keep arriving after the founder is gone, the ad budget is rationalized, and the logo on the door has changed.
The diligence room has caught up to this. The question is whether the founders walking into it have. The ones who built brand capital on purpose, years before the process, are the ones who get to argue for the premium, and win it. Everyone else finds out, too late, that the brand was on the balance sheet all along.
